Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 11/2017

01-11-2017 | Original paper

Prostate cancer clinical presentation, incidence, mortality and survival in Guadeloupe over the period 2008–2013 from a population-based cancer registry

Authors: J. Deloumeaux, B. Bhakkan, R. Eyraud, F. Braud, N. Manip M’Ebobisse, P. Blanchet, L. Brureau

Published in: Cancer Causes & Control | Issue 11/2017

Login to get access

Abstract

Purpose

The Caribbean population of Guadeloupe has one of the highest incidence rates of prostate cancer worldwide. In 2008, a population-based cancer registry was set up for the monitoring of cancer incidence in the aftermath of the environmental pollution with chlordecone, a persistent organochlorine insecticide formerly used in banana plantations. We describe the clinical presentation, incidence, mortality and survival of prostate cancer for the period 2008–2013.

Methods

The Guadeloupe cancer registry has been routinely collecting all incident cases of cancer since 2008. We compared age-specific incidence rates between different populations, and calculated incidence and mortality rates standardized to the world population. Kaplan–Meier observed survival and estimated age-standardized net survival were calculated by category for age, PSA level, and Gleason score using the Pohar-Perme method.

Results

Overall, 3,295 cases of prostate cancer were recorded. World-standardized incidence and mortality were respectively 184.1 [177.8–190.4] and 23.9 [21.9–25.7] per 100,000 person-years. At diagnosis, the mean age of patients was 68 ± 9.6 years old and 22% were aged over 75. Median PSA level was 8.9 [IQR: 6.0–16.0] and 13.6% of the patients had a Gleason ≥ 8. Five-year observed and net survivals were, respectively, 79.6% [77.9–81.2] and 90.7% [88.6–92.8].

Conclusion

The incidence of prostate cancer in Guadeloupe is among the highest in the world, along with those of the neighboring Caribbean countries and US African-Americans. We observed no decrease in incidence rates, and a decreasing but non-significant trend in mortality rates, which nonetheless remain higher than in high-income countries. Many Genome-Wide Association Studies are conducted to identify genetic markers involved in prostate cancer risk. In the Caribbean, complementary studies on both lifestyle and behavioral factors should highlight potential common risks among populations who share both genetic and environmental characteristics.
Literature
1.
2.
3.
Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94(13):981–990CrossRefPubMed
4.
5.
6.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer. Accessed 21 Jan 2017
7.
Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B (2004) Human prostate cancer risk factors. Cancer 101:2371–2490. doi:10.​1002/​cncr.​20408 CrossRefPubMed
8.
9.
Bergman Å, Heindel JJ, Jobling S, Kidd K, Zoeller TR (2013) State of the science of endocrine disrupting chemicals 2012, 2013 edn. United Nations Environment Programme and the World Health Organization.
10.
11.
Cabidoche YM, Achard R, Cattan P, Clermont-Dauphin C, Massat F, Sansoulet J (2009) Long-term pollution by chlordecone of tropical volcanic soils in the French west indies: a simple leaching model accounts for current residue. Environ Pollut 157(5):1697–1705. doi:10.​1016/​j.​envpol.​2008.​12.​015 CrossRefPubMed
12.
13.
Dromard CR, Bodiguel X, Lemoine S, Bouchon-Navaro Y, Reynal L, Thouard E, Bouchon C (2016) Assessment of the contamination of marine fauna by chlordecone in Guadeloupe and Martinique (Lesser Antilles). Environ Sci Pollut Res 23(1):73–80. doi:10.​1007/​s11356-015-4732-z CrossRef
14.
Charlotte DR, Yolande BN, Cordonnier S, Claude B (2016) The invasive lionfish, Pterois volitans, used as a sentinel species to assess the organochlorine pollution by chlordecone in Guadeloupe (Lesser Antilles). Mar Pollut Bull. doi:10.​1016/​j.​marpolbul.​2016.​04.​012 PubMed
15.
16.
17.
18.
Doll R, Payne P (1966) Cancer incidence in five continents, vol 1. Union Internationale Contre le Cancer, GenevaCrossRef
19.
Segi M (1960) Cancer mortality for selected sites in 24 countries (1950–57). Department of Public Health, Tohoku University of Medicine, Sendai
20.
21.
Kim HJ, Fay P, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Statistics in Medicine 19(3):335–351CrossRefPubMed
22.
23.
24.
Roche L, Danieli C, Belot A, Grosclaude P, Bouvier AM, Velten M, Iwaz J, Remontet L, Bossard N (2013) Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods. Int J Cancer 132(10):2359–2369. doi:10.​1002/​ijc.​27830 CrossRefPubMed
25.
26.
Smith DS, Carvalhal GF, Mager DE, Bullock AD, Catalona WJ (1998) Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 160(5):1734–1738CrossRefPubMed
27.
28.
29.
30.
Lafontaine A, Hanikenne M, Boulangé-Lecomte C, Forget-Leray J, Thomé JP, Gismondi E (2016) Vitellogenin and vitellogenin receptor gene expression and 20-hydroxyecdysone concentration in Macrobrachium rosenbergii exposed to chlordecone. Environ Sci Pollut Res Int 23(20):20661–20671CrossRefPubMed
31.
32.
33.
Bassett JK, Severi G, Baglietto L, MacInnis RJ, Hoang HN, Hopper JL, English DR, Giles GG (2012) Weight change and prostate cancer incidence and mortality. Int J Cancer 131(7):1711–1719. doi:10.​1002/​ijc.​27414 CrossRefPubMed
34.
Prevention CfDCa (2009) Differences in prevalence of obesity among black, white, and Hispanic adults—United States, 2006–2008. MMWR Morb Mortal Wkly Rep 58 (27):740–744
35.
Khan S, Cai J, Nielsen ME, Troester MA, Mohler JL, Fontham ET, Hendrix LH, Farnan L, Olshan AF, Bensen JT (2016) The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. Cancer Causes Control 27(12):1475–1485. doi:10.​1007/​s10552-016-0828-0 CrossRefPubMed
36.
37.
Daigre JL, Atallah A, Boissin JL, Jean-Baptiste G, Kangambega P, Chevalier H, Balkau B, Smadja D, Inamo J (2012) The prevalence of overweight and obesity, and distribution of waist circumference, in adults and children in the French Overseas Territories: the PODIUM survey. Diabetes Metab 38(5):404–411. doi:10.​1016/​j.​diabet.​2012.​03.​008 CrossRefPubMed
38.
39.
40.
Razzaghi H, Quesnel-Crooks S, Sherman R, Joseph R, Kohler B, Andall-Brereton G, Ivey MA, Edwards BK, Mery L, Gawryszewski V, Saraiya M (2016) Leading causes of cancer mortality—Caribbean Region, 2003–2013. Morb Mortal Wkly Rep 65(49):1395–1400. doi:10.​15585/​mmwr.​mm6549a3 CrossRef
41.
42.
Walsh PC (2005) Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. J Urol 174(4 Pt 1):1294–1295CrossRefPubMed
43.
Robbins AS, Yin D, Parikh-Patel A (2007) Differences in prognostic factors and survival among White men and Black men with prostate cancer, California, 1995–2004. Am J Epidemiol 166(1):71–78. doi:10.​1093/​aje/​kwm052 CrossRefPubMed
44.
Cancel-Tassin G, Romana M, Gaffory C, Blanchet P, Cussenot O, Multigner L (2015) Region 2 of 8q24 is associated with the risk of aggressive prostate cancer in Caribbean men of African descent from Guadeloupe (French West Indies). Asian J Androl 17(1):117–119. doi:10.​4103/​1008-682X.​135127 CrossRefPubMed
45.
46.
Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP, Group CW (2015) Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385(9972):977–1010. doi:10.​1016/​S0140-6736(14)62038-9 CrossRefPubMed
47.
48.
49.
50.
51.
52.
Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, Freedman ML, Rivers B, Green BL, Kumar N (2009) Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer 4(Suppl 1):S2. doi:10.​1186/​1750-9378-4-S1-S2 CrossRefPubMedPubMedCentral
Metadata
Title
Prostate cancer clinical presentation, incidence, mortality and survival in Guadeloupe over the period 2008–2013 from a population-based cancer registry
Authors
J. Deloumeaux
B. Bhakkan
R. Eyraud
F. Braud
N. Manip M’Ebobisse
P. Blanchet
L. Brureau
Publication date
01-11-2017
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 11/2017
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0962-3

Other articles of this Issue 11/2017

Cancer Causes & Control 11/2017 Go to the issue

Original paper

Experience with curative radiotherapy for cervix cancer in the Bahamas for 2006–2016

Original paper

Sinonasal malignancies: incidence and histological distribution in Jamaica, 1973–2007

Original paper

Prevalence of oral HPV infection among healthy individuals and head and neck cancer cases in the French West Indies

Original paper

Gatekeepers’ perceptions of the quality and availability of services for breast and cervical cancer patients in the English-speaking Windward Islands: an exploratory investigation

Original paper

Kaiso is highly expressed in TNBC tissues of women of African ancestry compared to Caucasian women

Original paper

Human papillomavirus genotype distribution in cervical samples among vaccine naïve Barbados women
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits